The importance of adjuvant formulation in the development of a tuberculosis vaccine
SL Baldwin, S Bertholet, VA Reese… - The Journal of …, 2012 - journals.aai.org
An effective protein-based vaccine for tuberculosis will require a safe and effective adjuvant.
There are few adjuvants in approved human vaccines, including alum and the oil-in-water …
There are few adjuvants in approved human vaccines, including alum and the oil-in-water …
[HTML][HTML] Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model
SL Baldwin, VA Reese, SE Larsen, E Beebe… - Plos one, 2021 - journals.plos.org
An estimated 10 million people developed tuberculosis (TB) disease in 2019 which
underscores the need for a vaccine that prevents disease and reduces transmission. The …
underscores the need for a vaccine that prevents disease and reduces transmission. The …
Protection and long-lived immunity induced by the ID93/GLA-SE vaccine candidate against a clinical Mycobacterium tuberculosis isolate
SL Baldwin, VA Reese, PD Huang… - Clinical and Vaccine …, 2016 - Am Soc Microbiol
Mycobacterium tuberculosis HN878 represents a virulent clinical strain from the W-Beijing
family, which has been tested in small animal models in order to study its virulence and its …
family, which has been tested in small animal models in order to study its virulence and its …
[HTML][HTML] The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
RN Coler, TA Day, R Ellis, FM Piazza, AM Beckmann… - npj Vaccines, 2018 - nature.com
Tuberculosis (TB) is the leading cause of infectious death worldwide. Development of
improved TB vaccines that boost or replace BCG is a major global health goal. ID93+ GLA …
improved TB vaccines that boost or replace BCG is a major global health goal. ID93+ GLA …
Protection of mice from Mycobacterium tuberculosis by ID87/GLA-SE, a novel tuberculosis subunit vaccine candidate
HP Windish, MS Duthie, G Ireton, E Lucas… - Vaccine, 2011 - Elsevier
Tuberculosis is a major health concern. Non-living tuberculosis (TB) vaccine candidates
may not only be safer than the current vaccine (BCG) but could also be used to boost BCG to …
may not only be safer than the current vaccine (BCG) but could also be used to boost BCG to …
Therapeutic Immunization against Mycobacterium tuberculosis Is an Effective Adjunct to Antibiotic Treatment
RN Coler, S Bertholet, SO Pine, MT Orr… - The Journal of …, 2013 - academic.oup.com
Background. Recent advances in rational adjuvant design and antigen selection have
enabled a new generation of vaccines with potential to treat and prevent infectious disease …
enabled a new generation of vaccines with potential to treat and prevent infectious disease …
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis
MT Orr, CB Fox, SL Baldwin, SJ Sivananthan… - Journal of Controlled …, 2013 - Elsevier
One third of the world is infected with Mycobacterium tuberculosis (Mtb) with eight million
new cases of active tuberculosis (TB) each year. Development of a new vaccine to augment …
new cases of active tuberculosis (TB) each year. Development of a new vaccine to augment …
[HTML][HTML] A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human
JT van Dissel, SA Joosten, ST Hoff, D Soonawala… - Vaccine, 2014 - Elsevier
Here, we report on a first-in-man trial where the tuberculosis (TB) vaccine Ag85B-ESAT-6
(H1) was adjuvanted with escalating doses of a novel liposome adjuvant CAF01. On their …
(H1) was adjuvanted with escalating doses of a novel liposome adjuvant CAF01. On their …
[HTML][HTML] Safety and immunogenicity of a thermostable ID93+ GLA-SE tuberculosis vaccine candidate in healthy adults
ZK Sagawa, C Goman, A Frevol, A Blazevic… - Nature …, 2023 - nature.com
Adjuvant-containing subunit vaccines represent a promising approach for protection against
tuberculosis (TB), but current candidates require refrigerated storage. Here we present …
tuberculosis (TB), but current candidates require refrigerated storage. Here we present …
Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31
EM Agger, I Rosenkrands, AW Olsen, G Hatch… - Vaccine, 2006 - Elsevier
In this study, we evaluated the potential of a novel synthetic adjuvant designated IC31 for the
ability to augment the immune response and protective efficacy of the well-known …
ability to augment the immune response and protective efficacy of the well-known …